Novartis Faces Investor Scrutiny Amid Troubling Drug Setbacks

As the workweek draws to a close, Novartis finds itself under the microscope of anxious investors following significant setbacks in its drug development pipeline. The pharmaceutical giant's recent challenges, particularly surrounding its acquisition strategy, have led to a sharp decline in its stock value, raising alarms over its future.

Setbacks in Drug Development

Novartis has experienced notable distress with its muscle-wasting disorder treatment, del-desiran, which failed in a crucial late-stage trial. This marks the second major disappointment for the company within days, sparking concerns among shareholders regarding the viability of its $12 billion acquisition of Avidity and other recent purchases. In response to these setbacks, Novartis shares plummeted by 11% in one day, erasing nearly $30 billion from its market valuation and reversing all gains made since the beginning of the year.

Challenges with Biologics and Patent Expirations

In a related concern, the Association for Accessible Medicines highlights a looming crisis for the pharmaceutical industry, revealing that 90% of biologics set to lose patent protection by 2034 lack lower-cost alternatives in development. Without these alternatives, American consumers may miss out on approximately $200 billion in potential savings over the next decade as 118 widely-used biologic drugs go off patent. These complex medications, often produced using living cells, have become significant revenue generators for drug companies, yet the market for newly launched biosimilars has faced a steep decline, dampening enthusiasm for their development.

Source: www.statnews.com